MedImmune to hire 800 in pipeline push

With plans to double the number of experimental therapies in its pipeline by 2010, MedImmune is laying plans to hire 800 new staffers by the end of this year, according to a report in the Washington Business Journal. That's a 25 percent increase in its workforce, which also swelled after AstraZeneca bought the Gaitherburg, MD-based developer and combined its operations with the UK's Cambridge Antibody Technology Group. Many of these new hires will be headed for the research department, which has ambitious plans for fast growth. MedImmune has outlined plans to provide 25 percent of AstraZeneca's late-stage therapies by 2010.

- read the report in the Washington Business Journal

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.